---
title: "Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264978313.md"
description: "Zacks Research upgraded Kura Oncology (NASDAQ:KURA) from a \"strong sell\" to a \"hold\" rating. Other analysts have varied opinions, with Wedbush setting a $36 target and HC Wainwright a $40 target. KURA opened at $10.16, with a market cap of $884.12 million. The company reported a loss of $0.85 EPS, missing estimates, but revenue was $20.75 million, exceeding expectations. Insider trading saw significant sales, and hedge funds have increased their stakes in the company recently."
datetime: "2025-11-08T11:20:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264978313.md)
  - [en](https://longbridge.com/en/news/264978313.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264978313.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264978313.md) | [繁體中文](https://longbridge.com/zh-HK/news/264978313.md)


# Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research

Kura Oncology (NASDAQ:KURA - Get Free Report) was upgraded by equities researchers at Zacks Research from a "strong sell" rating to a "hold" rating in a report issued on Wednesday,Zacks.com reports.

-   Is Kintara Therapeutics A Hidden Gem?

KURA has been the subject of a number of other research reports. Wedbush reiterated an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a report on Monday, October 20th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Guggenheim began coverage on Kura Oncology in a research report on Thursday, September 4th. They set a "neutral" rating on the stock. Finally, JMP Securities reiterated a "market outperform" rating and set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, October 20th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and an average target price of $24.67.

Get **Kura Oncology** alerts:

**View Our Latest Stock Report on Kura Oncology**

## Kura Oncology Price Performance

KURA opened at $10.16 on Wednesday. The business has a fifty day moving average of $9.17 and a 200 day moving average of $7.30. The stock has a market cap of $884.12 million, a P/E ratio of -4.10 and a beta of 0.35. The company has a quick ratio of 6.16, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $19.73.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to analysts' expectations of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. As a group, sell-side analysts anticipate that Kura Oncology will post -2.44 EPS for the current year.

## Insider Buying and Selling at Kura Oncology

In related news, insider Brian T. Powl sold 8,891 shares of the company's stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $79,485.54. Following the transaction, the insider directly owned 99,676 shares of the company's stock, valued at $891,103.44. This represents a 8.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Teresa Brophy Bair sold 8,805 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $78,716.70. Following the completion of the sale, the insider owned 148,043 shares of the company's stock, valued at approximately $1,323,504.42. This trade represents a 5.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 78,058 shares of company stock valued at $697,839. Corporate insiders own 6.40% of the company's stock.

## Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of the stock. Cerity Partners LLC acquired a new stake in Kura Oncology in the 1st quarter worth approximately $210,000. CWM LLC raised its holdings in shares of Kura Oncology by 892.8% in the first quarter. CWM LLC now owns 28,353 shares of the company's stock worth $187,000 after buying an additional 25,497 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Kura Oncology by 93.8% in the first quarter. Jennison Associates LLC now owns 138,532 shares of the company's stock worth $914,000 after buying an additional 67,035 shares during the last quarter. 1492 Capital Management LLC lifted its stake in shares of Kura Oncology by 25.4% during the first quarter. 1492 Capital Management LLC now owns 429,746 shares of the company's stock worth $2,836,000 after buying an additional 87,148 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Kura Oncology by 23.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,784 shares of the company's stock worth $216,000 after buying an additional 6,154 shares during the period.

## Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

## See Also

-   Five stocks we like better than Kura Oncology
-   Investing in Travel Stocks Benefits
-   CAVA Stock Looking for Direction After Earnings Miss
-   Utilities Stocks Explained – How and Why to Invest in Utilities
-   3 Small AI Stocks Ready to Explode (All Under $20)
-   Best Aerospace Stocks Investing
-   After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms

_This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._

## Should You Invest $1,000 in Kura Oncology Right Now?

Before you consider Kura Oncology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.

While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [Kura Oncology, Inc. (KURA.US)](https://longbridge.com/en/quote/KURA.US.md)

## Related News & Research

- [Research Analysts Set Expectations for Kura Oncology FY2030 Earnings](https://longbridge.com/en/news/271652278.md)
- [Jim Cramer discusses Kura Oncology as a speculative bet](https://longbridge.com/en/news/270408678.md)
- [AAA: Michigan gas prices rise again](https://longbridge.com/en/news/281019895.md)
- [The $805 monthly reality: Why the $45,859 MSRP is a 2026 trap](https://longbridge.com/en/news/281003665.md)
- [SEA (NYSE:SE) Insider Jingye Chen Sells 800 Shares](https://longbridge.com/en/news/280766932.md)